NARDA SHIPP: Open Payments
NPI 1811140114 · LEXINGTON, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$221 in 10 payments from 6 companies in 2025. Trend: 2023 $295 · 2024 $404 · 2025 $221
Food & beverage: $221
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 2 | $56 |
| ABBVIE INC. | 2 | $45 |
| Neurocrine BioSciences, Inc. | 2 | $40 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| Axsome Therapeutics, Inc. | 1 | $30 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
Products named: FANAPT, VRAYLAR, INGREZZA, Auvelity, NUEDEXTA, Qelbree, REXULTI.
Industry payments across KY — which companies pay providers there.
